Company profile
Otsuka Pharmaceutical
Diversified pharma; vasopressin-antagonist franchise (tolvaptan)
4578 · TSE (Otsuka Pharmaceutical Co., Ltd. is NOT separately listed — it is a wholly-owned subsidiary of Otsuka Holdings Co., Ltd. TSE code 4578 and the financial reports shown here are the listed parent's consolidated figures, covering the whole Otsuka group rather than this subsidiary alone. The assets listed are Otsuka Pharmaceutical's. Source: https://www.otsuka.co.jp/en/company/overview/) · Japan
Public Market Listing
Live quotes, historical charts, and market capitalization for Otsuka Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(10 total)
| Target & Modality | |||
|---|---|---|---|
Aripiprazole (Abilify Maintena)(Abilify Maintena) | Approved | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D2/D3 and serotonin 5-HT1A receptor · Dopamine D2 receptor (partial agonist)Small molecule | Schizophrenia |
Aripiprazole (Abilify MyCite)(Abilify MyCite) | Approved | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)Combination | Schizophrenia |
Aripiprazole (Abilify)(Abilify) | Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Schizophrenia |
Brexpiprazole (Rexulti)(Rexulti) | Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Alzheimer's DiseaseMajor Depressive DisorderSchizophrenia |
difamilast(Moizerto / Adquey) | Approved | PDE4Small molecule | Atopic Dermatitis |
Tolvaptan(Samsca / Jinarc) | Approved | Vasopressin V2 receptorSmall molecule | Heart FailureChronic Kidney Disease |
OPC-61815No recent activity | Phase 3 | Vasopressin V2 receptorSmall molecule | Heart Failure |
| Phase 3 | TAAR1 (trace amine-associated receptor 1)Small molecule | Schizophrenia | |
| Phase 2 | Integrin β7 (active-conformer epitope recognized by the MMG49 antibody)Cell therapy | Multiple Myeloma | |
| Phase 1 | Undisclosed / early pipelineSmall molecule | Major Depressive DisorderSchizophrenia |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.